R & D

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial

 This material is intended to notify the press release issued on March 30 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click  https://www.bms.com/media/press-releases.html for the original press release.